GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq: GNVC) today announced that it has reached agreement with the U.S. Food and Drug Administration to proceed with endoscopic ultrasound administration (EUS) of TNFerade™ as an additional option to percutaneous injection (PTA) for patients participating in its pivotal clinical trial for locally advanced pancreatic cancer (PACT).
